These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22583338)

  • 1. Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients.
    Lo YC; Ho HC; Wu MJ; Chen CH; Cheng CH; Yu TM; Chuang YW; Huang ST; Yang CK; Shu KH
    Ren Fail; 2012; 34(7):856-61. PubMed ID: 22583338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 receptor antagonists for kidney transplant recipients.
    Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
    Sun ZJ; Du X; Su LL; Zhang XD; Wang W
    Transplant Proc; 2015 Oct; 47(8):2439-45. PubMed ID: 26518947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation.
    Hammond EB; Taber DJ; Weimert NA; Egidi MF; Bratton CF; Lin A; McGillicuddy JW; Chavin KD; Baliga PK
    Clin Transplant; 2010; 24(1):40-7. PubMed ID: 19236436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody induction therapy for lung transplant recipients.
    Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis.
    Zhang Y; Jin W; Cai X
    Ann Med; 2017 Aug; 49(5):365-376. PubMed ID: 27813419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.
    Hellemans R; Hazzan M; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Noël C; Abramowicz D
    Am J Transplant; 2015 Jul; 15(7):1923-32. PubMed ID: 25707875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
    Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
    Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL; Ramos E; Lin A; Vincenti F;
    Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
    Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
    Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
    Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database.
    Jindal RM; Das NP; Neff RT; Hurst FP; Falta EM; Elster EA; Abbott KC
    Am J Nephrol; 2009; 29(6):501-8. PubMed ID: 19060477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.